Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse

Клеточное старение способствует неблагоприятным эффектам химиотерапии и рецидиву рака
Marco Demaria, Monique N. O’Leary, Jianhui Chang, Lijian Shao, Su Liu, Fatouma Alimirah, Kristin Lynn Koenig, Catherine T. Le, Natalia Mitin, Allison Mary Deal, Shani Malia Alston, Emmeline C. Academia, Sumner E. Kilmarx, Alexis Valdovinos, Boshi Wang, Alain de Bruin, Brian Keith Kennedy, Simon Melov, Daohong Zhou, Norman E. Sharpless, Hyman Bernard Muss, Judith Campisi
2016-12-15

cancer recurrencecellular senescencechemotherapy toxicitysenescence-associated secretory phenotypetherapy-induced senescent cells
Cellular senescence suppresses cancer by irreversibly arresting cell proliferation. Senescent cells acquire a proinflammatory senescence-associated secretory phenotype. Many genotoxic chemotherapies target proliferating cells nonspecifically, often with adverse reactions. In accord with prior work, we show that several chemotherapeutic drugs induce senescence of primary murine and human cells. Using a transgenic mouse that permits tracking and eliminating senescent cells, we show that therapy-induced senescent (TIS) cells persist and contribute to local and systemic inflammation. Eliminating TIS cells reduced several short- and long-term effects of the drugs, including bone marrow suppression, cardiac dysfunction, cancer recurrence, and physical activity and strength. Consistent with our findings in mice, the risk of chemotherapy-induced fatigue was significantly greater in humans with increased expression of a senescence marker in T cells prior to chemotherapy. These findings suggest that senescent cells can cause certain chemotherapy side effects, providing a new target to reduce the toxicity of anticancer treatments. SIGNIFICANCE: Many genotoxic chemotherapies have debilitating side effects and also induce cellular senescence in normal tissues. The senescent cells remain chronically present where they can promote local and systemic inflammation that causes or exacerbates many side effects of the chemotherapy. Cancer Discov; 7(2); 165-76. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 115.
1
Eliminating therapy-induced senescent cells reduces chemotherapy-associated bone marrow suppression, cardiac dysfunction, cancer recurrence, reduced physical activity, and muscle weakness in mice.
2
Higher expression of a senescence marker in human T cells before chemotherapy is associated with greater risk of chemotherapy-induced fatigue.
3
Senescent cells represent a potential therapeutic target for reducing chemotherapy toxicity and relapse.
4
Several genotoxic chemotherapeutic drugs induce cellular senescence in primary murine and human cells.
5
Therapy-induced senescent cells persist after treatment and contribute to local and systemic inflammation.

Chemotherapy-induced senescent (TIS) cells in normal tissues and their effects in mice and humans

The contribution of persistent TIS cells and their inflammatory secretory phenotype to chemotherapy toxicity, adverse effects, and cancer relapse

Publication Details
Publication Date
2016-12-15
Journal
Cancer Discovery
Publisher
American Association for Cancer Research
ISSN
2159-8274
Cited by
1452
Access Type
Author Information
Authors
Marco Demaria
Monique N. O’Leary
Jianhui Chang
Lijian Shao
Su Liu
Fatouma Alimirah
Kristin Lynn Koenig
Catherine T. Le
Natalia Mitin
Allison Mary Deal
Shani Malia Alston
Emmeline C. Academia
Sumner E. Kilmarx
Alexis Valdovinos
Boshi Wang
Alain de Bruin
Brian Keith Kennedy
Simon Melov
Daohong Zhou
Norman E. Sharpless
Hyman Bernard Muss
Judith Campisi
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%